HomeNewsBusinessPharma weekly wrap: IHH may get its offer approved, but getting Fortis back on track remains a challenge

Pharma weekly wrap: IHH may get its offer approved, but getting Fortis back on track remains a challenge

To consummate the deal, the IHH offer will now need the approval of Fortis' shareholders and the Competition Commission of India (CCI). According to the Fortis board, all this should not take more than 75 days

July 16, 2018 / 14:06 IST
Story continues below Advertisement

Viswanath Pilla Moneycontrol News

This past week saw Fortis Healthcare's board recommend IHH Healthcare's bid for a stake in the company to its shareholders, bringing the curtains down on a saga that began in February.

Malaysian healthcare provider IHH Healthcare outbid the Manipal-TPG consortium to emerge as the winner in the race for Fortis, with a binding offer to invest Rs 4,000 crore by way of preferential allotment.

Story continues below Advertisement

The allotment will take place at Rs 170 a share, which is at a 20 percent premium to Fortis' current market price.

Manipal-TPG offered to infuse Rs 2,100 crore by buying shares through a preferential allotment at Rs 160 per share. It also offered to buy out the stake held by private equity investors in Fortis' subsidiary SRL Diagnostics for Rs 1,134 crore.